Clinical study on the organ correlation in acute liver diseases

Clinical study on the correlation between liver, heart, lung, and kidney in acute liver failure, or acute-on-chronic liver disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030230206

Enrollment

Registered

2023-07-05

Start date

2023-06-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver diseases Acute liver failure, acute on chronic liver diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with liver disease who were admitted due to some exacerbating factor (liver failure, infection, hemorrhage, encephalopathy, ascites, dehydration, electrolyte abnormalities, etc.) (2) Patients aged 18 years or older (iii) Patients who have received a full explanation of the disease condition and treatment methods, have received an explanation of the study, and have obtained the free and voluntary written consent of the patient or a surrogate after full understanding of the study.

Exclusion criteria

Exclusion criteria: Patients deemed unsuitable as subjects by the study investigator or sub-investigator

Design outcomes

Primary

Measure	Time frame
The frequency of cardiomyopathy, pulmonary hypertension, hepatopulmonary syndrome, and hepatorenal syndrome in ACLF and acute liver failure will be investigated, as well as their causes, risk factors and biomarkers for their development, and their subsequent clinical course.	—

Secondary

Measure	Time frame
a. To examine the relationship between liver reserve test values (blood biochemistry, Child-Pugh score, MELD score, liver elasticity) and cardiac function factors, pulmonary hypertension factors, hepatopulmonary syndrome factors, and hepatorenal syndrome factors. b. To examine the association between portal vein hemodynamic severity (hepatic venous pressure gradient, Doppler blood flow factors of portal vein and short circuit) and cardiac function factors, pulmonary hypertension factors, hepatopulmonary syndrome factors, and hepatorenal syndrome factors. c. To examine changes in cardiac function factors, pulmonary hypertension factors, hepatopulmonary syndrome factors, and hepatorenal syndrome factors and their factors after 3 months. d. To examine the association between prognosis and cardiac function factors, pulmonary hypertension factors, hepatopulmonary syndrome factors, and hepatorenal syndrome factors. e. Examine differences in markers of cell death, endothelin, and cytokines and their potential as biomarkers depending on the site of angiography. In addition, we will examine whether markers of cell death, endothelin, and cytokines in urinalysis are biomarkers for prognosis, cardiac function, pulmonary hypertension, hepatopulmonary syndrome, and hepatorenal syndrome.	—

Measure

Time frame

a. To examine the relationship between liver reserve test values (blood biochemistry, Child-Pugh score, MELD score, liver elasticity) and cardiac function factors, pulmonary hypertension factors, hepatopulmonary syndrome factors, and hepatorenal syndrome factors. b. To examine the association between portal vein hemodynamic severity (hepatic venous pressure gradient, Doppler blood flow factors of portal vein and short circuit) and cardiac function factors, pulmonary hypertension factors, hepatopulmonary syndrome factors, and hepatorenal syndrome factors. c. To examine changes in cardiac function factors, pulmonary hypertension factors, hepatopulmonary syndrome factors, and hepatorenal syndrome factors and their factors after 3 months. d. To examine the association between prognosis and cardiac function factors, pulmonary hypertension factors, hepatopulmonary syndrome factors, and hepatorenal syndrome factors. e. Examine differences in markers of cell death, endothelin, and cytokines and their potential as biomarkers depending on the site of angiography. In addition, we will examine whether markers of cell death, endothelin, and cytokines in urinalysis are biomarkers for prognosis, cardiac function, pulmonary hypertension, hepatopulmonary syndrome, and hepatorenal syndrome.

—

Contacts

Public ContactTakayuki Kondo

Chiba University Hospital

takakon@chiba-u.jp+81-432227171

Outcome results